6MM macrophage activation syndrome market eyes 24.7% CAGR growth until 2034

The market was valued at $110m in 2024.

The macrophage activation syndrome sector in the six major markets (6MM) is expected to expand at a compound annual growth rate of 24.7% until 2034, according to a DelveInsight report.

The sector's expansion is attributed to broadened treatment options, improved survival outcomes, and the launch of emerging therapies.

The market was valued at $110m in 2024, with the US accounting for 91% of the market during the period.

Current treatments include glucocorticoids, cytokine-targeted biologics, and GAMIFANT (emapalumab). Meanwhile, key industry players are developing new treatment drugs, which are expected to enter the market in the coming years, the report said.

Approximately 22,000 diagnosed cases were reported in the 6MM in 2024, a figure expected to rise over the forecast period due to autoimmune, autoinflammatory, and infectious diseases.

MAS affects both paediatric and adult populations, commonly linked to systemic juvenile idiopathic arthritis and adult-onset Still’s disease.

6MM =  US, Germany, France, Italy, Spain, and the UK.